Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an observational cohort study designed to (1) evaluate whether Gallium-68 (68Ga)-labeled fibroblast activation protein inhibitor ligand LM3 (68Ga-FAPI-LM3) positron emission tomography/computed tomography (PET/CT) improves the accuracy of nasopharyngeal carcinoma (NPC) staging, and (2) determine whether Gallium-68-labeled programmed death-ligand 1 (68Ga-PD-L1) PET/CT imaging parameters can provide early prediction of response to neoadjuvant immunotherapy. The study will assess the sensitivity and specificity of each tracer for staging and for predicting therapeutic response, analyze changes in tumor uptake parameters on 68Ga-FAPI-LM3 and 68Ga-PD-L1 PET/CT before and after treatment, and compare treatment efficacy and survival outcomes between patients with different degrees of residual PET uptake and between those who did and did not receive neoadjuvant immunotherapy. The primary question it aims to answer is: Does 68Ga-FAPI-LM3 PET/CT improve the accuracy of NPC staging, and can 68Ga-PD-L1 PET/CT imaging parameters provide an early prediction of response to neoadjuvant immunotherapy? Participants will be patients with biopsy-proven nasopharyngeal carcinoma who undergo 68Ga-FAPI-LM3 and/or 68Ga-PD-L1 PET/CT as part of clinical care or a research protocol. Tumor uptake metrics (e.g., maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic/volumetric indices) will be measured pre- and post-treatment; diagnostic performance (sensitivity, specificity) and associations between uptake changes and clinical outcomes (response rates, progression-free and overall survival) will be calculated.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-70 lat, każda płeć
- •Potwierdzony biopsją rak gardła nosowego (typ nieniszczący)
- •Zaawansowanie choroby I-IVA bez przerzutów do odległych narządów
- •Dobry stan ogólny (ECOG 0-1)
- •Brak poprzedniego leczenia przeciwnowotworowego (radioterapia, chemioterapia, immunoterapia)
- •Brak przeciwwskazań do radioterapii lub chemioterapii
- •Prawidłowe funkcjonowanie wątroby, nerek i szpiku kostnego
- •Świadoma zgoda na udział w badaniu i możliwość uczestniczenia w wizytach kontrolnych
✗ Disqualifies
- •Inny typ raka gardła nosowego (keratynizujący lub bazaloidalny)
- •Obecny lub wcześniejszy inny nowotwór złośliwy (z wyjątkiem wybranych zmian skórnych)
- •Jednoczesny udział w innym badaniu klinicznym
- •Ciąża lub okres karmienia piersią
- •Niekontrolowane choroby serca (zaburzenia rytmu, zawał, niewydolność serca)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- August 27, 2026
- Sex
- No restrictions
Locations (1)
The First Affiliated Hospital of Xiamen University
Xiamen, China
Trial contact
Qin Lin, Doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.